Niagen Bioscience, Inc. NAGE
3.05
0.04
1.33%
as of 25 Sep
- Market cap
- $238.2M
- P/E
- 15.2×
Follow NAGE
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
38.90% | 28.35% | 27.07% | 21.80% | |
| 26.42% | 19.90% | 19.05% | 16.14% | ||
ROIC |
188.93% | 86.63% | 51.81% | 41.95% | |
Return on Tangible Assets |
28.22% | 22.22% | 22.29% | 19.04% | |
Average Days of Receivables |
24.90 | 27.47 | 36.57 | 24.26 | |
Free Cash Flow per Share |
0.27 | 0.17 | 0.12 | 0.14 | |
Free Cash Flow |
21.15 | 13.21 | 9.91 | 11.47 | |
Capital Expenditures |
(0.26) | (0.29) | 5.48 | 5.53 | |
Piotroski F-Score |
6.00 | 5.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
15.86% | 9.56% | 2.97% | 3.99% | |
Accounts Receivable Turnover |
15.99 | 14.78 | 12.96 | 14.16 | |
Accounts Payable Turnover |
4.58 | 4.79 | 3.90 | 3.99 | |
Inventory Turnover |
3.07 | 3.12 | 2.65 | 2.63 | |
Average Days of Payables |
103.29 | 85.23 | 104.03 | 74.63 | |
Days of Inventory on Hand |
152.32 | 161.24 | 188.18 | 163.20 | |
Tax Rate |
(0.02) | (0.04) | (0.05) | (0.06) | |
Research and Development Expense of Revenue |
4.76% | 4.89% | 5.02% | 5.03% | |
Selling, General and Administrative Expense of Revenue |
43.66% | 48.34% | 50.75% | 52.53% | |
Share Based Compensation of Revenue |
4.07% | 4.69% | 5.14% | 5.38% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.05 | 0.78 | 0.24 | 0.37 | |
Depreciation/Fixed assets |
0.52 | 0.59 | 0.68 | 0.78 | |
Capex/Depreciation |
(0.34) | (0.37) | 6.22 | 5.66 | |
Revenue per Share |
1.56 | 1.63 | 1.63 | 1.63 | |
Operating CF per Share |
0.27 | 0.17 | 0.06 | 0.08 | |
Capex per Share |
0.00 | 0.00 | 0.07 | 0.07 | |
Capex to Sales |
0.00 | 0.00 | (0.04) | (0.04) | |
Net Profit Margin |
16.38% | 13.43% | 14.29% | 12.39% |
Columns are period end dates